OpenCapitalBeta

Calendar Stocks Metrics

/

Stocks
Royalty Pharma
Business Segments
Products & Services
Research and development commitment

Research and development commitment

Royalty Pharma·Products & Services·3 segments

Breakdown

Segments

Total Funding, TEV-408View metric

Phase 2b, TEV-408View metric

Phase 3, TEV-408View metric

Navigation

Earnings Calendar
Stocks
Pricing
About
Methodology

Connect

Claude (MCP)
ChatGPT (MCP)
Portfolio (Plaid)

Legal

Privacy Policy
Terms of Service
Cookie Policy
SEC EDGAR
support@opencapital.sh

© 2026 OpenCapital. All rights reserved.

Data sourced from SEC filings — methodology

OpenCapital is not affiliated with or endorsed by the U.S. Securities and Exchange Commission (SEC). All data is sourced from publicly available SEC filings.

OpenCapital

Segment	Q1 '26
Phase 3, TEV-408	$425.00M
Phase 2b, TEV-408	$75.00M
Total	$500.00M